Clinical and economic outcomes associated with amlodipine/renin–angiotensin system blocker combinations

Therapeutic Advances in Cardiovascular Disease

Volumn 7, Issue 1, 2013, Pages 27-39

  Ferrario, Carlos M ^a   Panjabi, Sumeet ^b   Buzinec, Paul ^c   Swindle, Jason P ^c  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b DAIICHI SANKYO INC   (United States)

^c OPTUM   (United States)

Author keywords

adherence; cardiovascular outcomes; fixed dose combinations; hypertension; retrospective claims analysis

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS BENAZEPRIL; AMLODIPINE PLUS OLMESARTAN; CANDESARTAN; EPROSARTAN; IRBESARTAN; LOSARTAN; OLMESARTAN; TELMISARTAN; VALSARTAN;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR RISK; COHORT ANALYSIS; DEMOGRAPHY; DESCRIPTIVE RESEARCH; DRUG COST; DRUG UTILIZATION; ECONOMIC EVALUATION; FEMALE; FOLLOW UP; HEALTH CARE COST; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADULT; AGED; AMLODIPINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; CALCIUM CHANNEL BLOCKERS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; IMIDAZOLES; INSURANCE CLAIM REVIEW; LINEAR MODELS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; RENIN-ANGIOTENSIN SYSTEM; RETROSPECTIVE STUDIES; TETRAZOLES; TREATMENT OUTCOME;

EID: 84873577082     PISSN: 17539447     EISSN: 17539455     Source Type: Journal    
DOI: 10.1177/1753944712470979     Document Type: Article

References (42)

1. Bailey J. Wan J. Tang J. Ghani M. Cushman W. (2010) Antihypertensive medication adherence, ambulatory visits, and risk of stroke and death. J Gen Intern Med 25: 495–503.
2. Bangalore S. Kamalakkannan G. Parkar S. Messerli F. (2007) Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 120: 713–719.
3. Bangalore S. Ley L. (2012) Improving treatment adherence to antihypertensive therapy: the role of single-pill combinations. Expert Opin Pharmacother 13: 345–355.
4. Black H. Elliott W. Neaton J. Grandits G. Grambsch P. Grimm R. Jr et al. (2001) Baseline characteristics and early blood pressure control in the CONVINCE trial. Hypertension 37: 12–18.
5. Brixner D. Jackson K. II Sheng X. Nelson R. Keskinaslan A. (2008) Assessment of adherence, persistence, and costs among valsartan and hydrochlorothiazide retrospective cohorts in free-and fixed-dose combinations. Curr Med Res Opin 24: 2597–2607.
6. Butler R. Davis T. Johnson W. Gardner H. (2011) Effects of nonadherence with prescription drugs among older adults. Am J Manag Care 17: 153–160.
7. Charlson M. Pompei P. Ales K. Mackenzie C. (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40: 373–383.
8. Chobanian A. Bakris G. Black H. Cushman W. Green L. Izzo J. Jr et al. (2003) The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report. J Am Med Assoc 289: 2560–2572.
9. Choo P. Rand C. Inui T. Lee M. Cain E. Cordeiro-Breault M. et al. (1999) Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy. Med Care 37: 846–857.
10. Christensen D. Williams B. Goldberg H. Martin D. Engelberg R. Logerfo J. (1994) Comparison of prescription and medical records in reflecting patient antihypertensive drug therapy. Ann Pharmacother 28: 99–104.
11. Cushman W. Ford C. Cutler J. Margolis K. Davis B. Grimm R. et al. (2002) Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich) 4: 393–404.
12. Egan B. Zhao Y. Axon R. (2010) US trends in prevalence, awareness, treatment, and control of hypertension, 1988–2008. J Am Med Assoc 303: 2043–2050.
13. Faulkner M. Hilleman D. (2001) Amlodipine/benazepril: fixed dose combination therapy for hypertension. Expert Opin Pharmacother 2: 165–178.
14. Flack J. Casciano R. Casciano J. Doyle J. Arikian S. Tang S. et al. (2002) Cardiovascular disease costs associated with uncontrolled hypertension. Manag Care Interface 15: 28–36.
15. Gerbino P. Shoheiber O. (2007) Adherence patterns among patients treated with fixed-dose combination versus separate antihypertensive agents. Am J Health Syst Pharm 64: 1279–1283.
16. Gradman A. Basile J. Carter B. Bakris G. Materson B. Black H. et al. (2010) Combination therapy in hypertension. J Am Soc Hypertens 4: 90–98.
17. Gupta A. Arshad S. Poulter N. (2010) Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 55: 399–407.
18. Heidenreich P. Trogdon J. Khavjou O. Butler J. Dracup K. Ezekowitz M. et al. (2011) Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 123: 933–944.
19. Hess G. Hill J. Lau H. Dastani H. Chaudhari P. (2008) Medication utilization patterns and hypertension-related expenditures among patients who were switched from fixed-dose to free-combination antihypertensive Therapy. P T 33: 652–666.
20. Leslie R. Gwadry-Sridhar F. Thiebaud P. Patel B. (2008) Calculating medication compliance, adherence, and persistence in administrative pharmacy claims databases. Pharm Program 1: 13–19.
21. Lloyd-Jones D. Adams R. Brown T. Carnethon M. Dai S. de Simone G. et al. (2010) Heart disease and stroke statistics – 2010 update: a report from the American Heart Association. Circulation 121: e46–e215.
22. Mazzaglia G. Ambrosioni E. Alacqua M. Filippi A. Sessa E. Immordino V. et al. (2009) Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation 120: 1598–1605.
23. Mccombs J. Nichol M. Newman C. Sclar D. (1994) The costs of interrupting antihypertensive drug therapy in a Medicaid population. Med Care 32: 214–226.
24. Neal B. Macmahon S. Chapman N. Blood Pressure Lowering Treatment Trialists’ Collaboration. (2000) Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists’ Collaboration. Lancet 356: 1955–1964.
25. Neutel J. (2011) Long-term blood pressure control: what can we do? Postgrad Med 123: 88–93.
26. Oparil S. Weber M. (2009) Angiotensin receptor blocker and dihydropyridine calcium channel blocker combinations: an emerging strategy in hypertension therapy. Postgrad Med 121: 25–39.
27. Paramore L. Halpern M. Lapuerta P. Hurley J. Frost F. Fairchild D. et al. (2001) Impact of poorly controlled hypertension on healthcare resource utilization and cost. Am J Manag Care 7: 389–398.
28. Pittman D. Tao Z. Chen W. Stettin G. (2010) Antihypertensive medication adherence and subsequent healthcare utilization and costs. Am J Manag Care 16: 568–576.
29. Psaty B. Furberg C. Kuller L. Cushman M. Savage P. Levine D. et al. (2001) Association between blood pressure level and the risk of myocardial infarction, stroke, and total mortality: the Cardiovascular Health Study. Arch Intern Med 161: 1183–1192.
30. Quan H. Sundararajan V. Halfon P. Fong A. Burnand B. Luthi J. et al. (2005) Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 43: 1130–1139.
31. Rizzo J. Simons W. (1997) Variations in compliance among hypertensive patients by drug class: implications for health care costs. Clin Ther 19: 1446–1457; discussion 1424–1445.
32. Roger V. Go A. Lloyd-Jones D. Benjamin E. Berry J. Borden W. et al. (2012) Executive summary: Heart disease and stroke statistics–2012 update: A report from the American Heart Association. Circulation 125: 188–197.
33. See S. (2001) Angiotensin II receptor blockers for the treatment of hypertension. Expert Opin Pharmacother 2: 1795–1804.
34. Sherrill B. Halpern M. Khan S. Zhang J. Panjabi S. (2011) Single-pill vs free-equivalent combination therapies for hypertension: a meta-analysis of health care costs and adherence. J Clin Hypertens (Greenwich) 13: 898–909.
35. Sica D. (2002) Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs 62: 443–462.
36. Sica D. (2003) Calcium channel blocker-related periperal edema: can it be resolved? J Clin Hypertens (Greenwich) 5: 291–294, 297.
37. Sokol M. Mcguigan K. Verbrugge R. Epstein R. (2005) Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 43: 521–530.
38. Tejada T. Fornoni A. Lenz O. Materson B. (2007) Combination therapy with renin-angiotensin system blockers: will amlodipine replace hydrochlorothiazide? Curr Hypertens Rep 9: 284–290.
39. United States (1996) Health Insurance Portability and Accountability Act of 1996. Public Law 104–191. US Statut Large 110: 1936–2103.
40. US Bureau of Labor Statistics, US Department of Labor (1999) Chained Consumer Price Index 1999. Available at: http://www.bls.gov/data/ (accessed 27 November 2012).
41. Yang W. Chang J. Kahler K. Fellers T. Orloff J. Wu E. et al. (2010) Evaluation of compliance and health care utilization in patients treated with single pill vs. free combination antihypertensives. Curr Med Res Opin 26: 2065–2076.
42. Zeng F. Patel B. Andrews L. Frech-Tamas F. Rudolph A. (2010) Adherence and persistence of single-pill ARB / CCB combination therapy compared to multiple-pill ARB / CCB regimens. Curr Med Res Opin 26: 2877–2887.